Viridian Therapeutics, Inc. VRDN Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s net income?
- Viridian Therapeutics, Inc. (VRDN) reported net income of -$104.9M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s net income changed year-over-year?
- Viridian Therapeutics, Inc.'s net income decreased by 20.7% year-over-year, from -$86.91M to -$104.9M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s net income has grown at a 44.1% compound annual growth rate (CAGR), from -$79.41M to -$342.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.